Menu Back toSession-5-Asia-Region-Updates

Pharmacovigilance and Risk Management Strategies Conference

Session 1: Asia Region Updates

Session Chair(s)

E. Stewart  Geary, MD

E. Stewart Geary, MD

  • Senior VP, Global Safety Officer, Director, Corporate Medical Affairs HQ
  • Eisai Co., Ltd., Japan

The session will provide an update on pharmacovigilance in India including the structure of the pharmacovigilance system and key regulations which clinical trial sponsors and marketing authorization holders must follow for compliance. A review of the new format for the Japanese package insert, with an emphasis on the presentation of safety information, along with the timelines and considerations for implementation will be described as well as an overall update on labeling in Asia. The new requirement for E2B (R3) reporting implementation in China for clinical trials as well as plans for post-marketing reporting will be explained as well as key issues to address in system implementation and vendor selection.

Learning Objective :

At the conclusion of this session, participants should be able to:

  • Describe current conditions and requirements for pharmacovigilance in India
  • Understand the issues which need to be addressed when planning E2B (R3) implementation in China
  • Anticipate the coming change in package insert format in Japan and its timeline for implementation as well as current movements for labeling in Asia


J Vijay  Venkatraman, MD, MBA

Post-Approval Pharmacovigilance Obligations for the Industry in India: Current Scenario

J Vijay Venkatraman, MD, MBA

  • Managing Director and CEO
  • Oviya MedSafe, India
Rie  Matsui, RPh

New Japanese Package Insert Format and Overview of Labeling in Asia

Rie Matsui, RPh

  • Senior Director, Regional Labeling Head for APAC
  • Pfizer, Japan
Stella  Xu

E2B (R3) Implementation for Pharmacovigilance Reporting in China

Stella Xu

  • Senior Manager, Drug Safety and Pharmacovigilance
  • dMed, China